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Summary and Key Points 
1. Esophageal cancer is classified histologically as squamous cell 
carcinoma or adenocarcinoma.1 
2. Worldwide, squamous cell carcinoma is the more common type of 
cancer of the esophagus. 
3. The incidence of esophageal adenocarcinoma has been rising in 
the developed nations, apparently due to its association with 
gastroesophageal reflux disease, obesity and Barrett’s esophagus. 
4. Squamous cell carcinoma is more common in a setting of tobacco 
and alcohol use. 
5. The tissue diagnosis of esophageal carcinoma is made by 
endoscopy with biopsy.
 
 
6. Staging workup is classically performed using endoscopy and/or 
barium swallow under fluoroscopy, CT and PET/CT. 
7. The American Joint Committee on Cancer (AJCC) tumor node 
metastasis (TNM) classification system is used to stage 
esophageal cancer. 
8. Multimodality treatment for local control and palliation is almost 
always indicated if the patient is able to tolerate it. Most esophageal 
carcinomas present at a fairly advanced stage because symptoms 
occur late in many patients, but early diagnosis improves 
outcomes.1 
9. The prognosis for most patients with esophageal cancer remains 
poor. Treatment is often focused on symptom relief. 
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Case Presentations 
1. A 50-year-old woman with a long history of heartburn presented to 
her primary care physician complaining of progressive difficulty 
swallowing solids, occasionally having to cough up food, and 10-
kilogram weight loss over the last 2 months. 
She is referred for upper endoscopy, which reveals a circumferential 
ulcerated and fungating mass at 35 cm from the incisors (Figure 1a). 
The endoscope cannot be advanced through the lesion. Ultrasound 
demonstrates the mass extends through the esophageal wall’s deep 
muscular layer (T3 lesion, Figure 1b) and one round, hypo echoic 
para-esophageal lymph node (N1) (Figure 1c) Biopsy from the 
lesion is read as demonstrating grade 2 adenocarcinoma with 
Barrett’s esophagus (Figure 1d). 
 
Figure 1. a) Endoscopic photograph of mass in lumen of esophagus. 
University of Massachusetts Medical School, Department of Medicine, 
Gastroenterology Division; b) Endoscopic ultrasound of mass in lumen of 
esophagus. University of Massachusetts Medical School, Department of 
Medicine, Gastroenterology Division; c) Endoscopic ultrasound of lumen of 
esophagus superior to mass. University of Massachusetts Department of 
Medicine, Gastroenterology Division; d) Invasive adenocarcinoma of the 
esophagus. Image courtesy of the University of Massachusetts Medical 
School, Department of Pathology. 
 
2. A 65-year-old man with 2 pack per day smoking history and 
consumption of 2-6 boilermakers per day over the last 45 years 
complains of severe sore throat, new onset cough on swallowing 
and difficulty getting bread to go down. 
Endoscopy demonstrates a mass at 20 cm from the incisors. The 
endoscope passes easily, and endoscopic ultrasound shows the 
lesion is confined to the esophageal wall, and no lymph nodes are 
visible (Figure 2a). Biopsy reveals well differentiated squamous 
cell carcinoma (Figure 2b). 
 
Figure 2a. Endoscopic ultrasound of mass in lumen of esophagus. Image 
courtesy of the University of Massachusetts Medical School, Department 
of Medicine, Gastroenterology Division. 
 
 
Figure 2b. Well differentiated squamous cell carcinoma. Image courtesy 
of the University of Massachusetts Medical School, Department of 
Pathology. 
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Introduction 
Esophageal cancer is one of the leading causes of cancer death 
worldwide, ranking eighth in incidence and sixth in mortality.2. It should be 
thought of as two distinct diseases, adenocarcinoma (AC), which usually 
occurs in the distal esophagus, and squamous cell carcinoma (SCC), 
which can occur anywhere in the esophagus, but more commonly involves 
the upper 2/3 of the organ. Cancers in the gastroesophageal junction are 
almost always adenocarcinomas and are treated and reported as 
esophageal cancers.3 
Epidemiology 
The American Cancer Society projects that approximately 16,940 new 
cases will be diagnosed in 2017 with approximately 12,720 male and 2970 
female deaths.4 Worldwide, esophageal cancer is the 6th most common 
cause of cancer death, and the 8th most common cancer.5 Risk increases 
with age. Incidence varies geographically with high prevalence in Asia, 
southern and eastern Africa and parts of France as compared to North 
America and the rest of Africa and Europe. SCC is more common than AC 
worldwide and continues to increase, especially in the esophageal cancer 
belt, across central Asia.6 The incidence of esophageal AC has been 
increasing in developed nations.7 The increasing incidence of AC in the 
United States is the reason that cancer of the esophagus is the only 
relatively common malignancy that is increasing in incidence, despite 
declining SCC. 
Worldwide, there is a male predominance of both AC8 and SCC9. In the 
United States, AC is concentrated in white males, while SCC remains 
more common in white females and black individuals of both sexes. 
Regional variation in incidence of both types strongly suggests a large 
environmental or lifestyle component to the etiology of these malignancies. 
Screening 
Screening may be useful in areas of the world where esophageal cancer 
is very common – northern China, for example- as early detection and 
treatment have been documented to improve survival statistics. But where 
the disease is rare, the chance of finding an early case is so low that the 
cost of finding an early case far exceeds the potential benefit, so screening 
is not indicated for the general population in the United States. Even for 
patients with Barrett’s esophagus (discussed below), screening may not 
be cost effective, except perhaps for patients found to have dysplasia, 
particularly high grade dysplasia, on initial endoscopy. 
Etiology 
Adenocarcinoma 
AC, which tends to occur in the lower third of the esophagus and 
gastroesophageal junction, is thought to be related to gastroesophageal 
reflux disease (GERD), obesity and Barrett’s esophagus. 
Obesity has been linked to an increase in the risk for esophageal AC, likely 
due to increased acid reflux related to elevated levels of abdominal 
adipose tissue (central obesity), or perhaps inflammatory substances 
secreted by fat cells. Physical activity appears to be protective. 
Barrett’s esophagus is a condition in which the normal squamous epithelial 
lining of the esophagus is replaced with columnar, glandular metaplastic 
cells apparently caused by chronic GERD (Figure 3). GERD is more 
common in obese patients, and so is Barrett’s esophagus. 
 
Figure 3. Barrett’s esophagus 100X: Biopsy of the gastroesophageal junction 
showing intestinal metaplasia that has crypts typically found in the intestine, and 
numerous Goblet cells in these glands that also are characteristic of intestinal 
epithelium. Image courtesy of the University of Massachusetts Medical School, 
Department of Pathology. 
The exact pathogenesis of Barrett’s is unclear; however it is thought to be 
due to repeated exposure to acid that results in inflammation with mucosal 
injury which may lead to intestinal metaplasia and ultimately dysplasia of 
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the epithelial lining. Patients diagnosed with Barrett’s have a 1-in-8 to 1-
in-14 risk of being diagnosed with AC of the esophagus.10 
Tobacco abuse is a moderate risk factor for developing AC; alcohol does 
not appear to be.9 There is some evidence of a small genetic contribution. 
There may be a genetic component to development of both Barrett’s and 
AC, since familial clusters have been seen.11 
Squamous cell carcinoma 
In contrast, both tobacco and alcohol are strongly associated with SCC of 
the esophagus, and when usage is combined they increase risk 
dramatically. Dietary and nutritional factors are also implicated in the 
development of SCC, especially diets rich in carbohydrates and fats and 
deficient in vitamins and minerals, consumption of very hot liquids (mate), 
betel nut chewing, especially when mixed with tobacco.12 
There are also genetic risks for SCC, including tylosis, an autosomal 
dominant disease that causes hyperkeratosis of palms and soles and is 
associated with SCC. Chinese studies suggest a genetic component 
increasing risk for heavy alcohol and tobacco use in some people. 
Protective Effects 
Overall esophageal cancer risk was 29% lower in the most physically 
active. AC risk was 32% lower, in the most physically active, independent 
of body mass index. A simple lifestyle intervention of increased physical 
activity may decrease the rate of esophagus AC. In one study, the risk of 
AC was 32% lower in the most active people, with an intermediate risk in 
people less active compared to sedentary people.13 Exercise appears to 
be protective against AC, partially by decreasing obesity, and partially by 
decreasing the inflammatory substances or by lowering fasting insulin 
levels and insulin resistance.14,15 
Interestingly, Helicobacter pylori (H. pylori) infection appears to be 
protective as well, perhaps because it ultimately decreases acid 
production. Consumption of high fiber diet, with vegetables and fruits, 
decreases the risk of both types of esophageal cancer.16 
Clinical Presentation 
Patients with any esophageal neoplasm are usually asymptomatic. But as 
tumor bulk increases, patients complain of dysphasia and report weight 
loss. The dysphagia usually begins with solid foods and is progressive, 
whereas dysphagia for liquids is a very late occurrence. This distinction 
helps differentiate (benign) motility disorders of the esophagus from 
obstructing neoplasms. 
Late symptoms include drooling from complete obstruction and inability to 
swallow the patient’s own oral secretions. Cough, hoarseness, back pain 
and retrosternal pain suggest locally advanced disease with possible 
invasion into the recurrent laryngeal nerve or the trachea. Tumors that 
bleed can cause hematemesis, fecal occult or manifest blood loss, and 
sometimes frank melena. 
The patient history is very important in esophageal diseases including 
cancer and must explore smoking and alcohol history, symptoms of reflux, 
and Barrett’s. Patients should be asked about prior endoscopy and often 
they will remember what the findings were, particularly if Barrett’s was 
discovered, as this would typically lead to subsequent and repeat 
endoscopic examinations. Problems with reflux over many years can be 
surmised from the use of antacids, calcium-containing over-the-counter 
tablets, and prescription drugs that reduce acid. As in all patients, family 
health history should be explored. 
On physical exam early esophageal cancer provides few clues to its 
presence. In advanced cases weight loss, cachexia, palpable lymph nodes 
in the supraclavicular fossae or abdominal masses are likely to be found. 
The patient’s nutritional status should be assessed, as this invariably will 
influence tolerance of therapy. 
Cancer of the esophagus irrespective of its type is among the most 
catabolic of human diseases, and weight loss beyond that expected from 
difficulty swallowing and alcohol abuse is common. A search for other 
causes of dysphagia is essential when first seeing these patients, with 
motility disorders such as achalasia and scleroderma high on the list of 
possibilities. Foreign body dysphagia rarely is longstanding enough to be 
confused with esophageal cancer, but esophageal strictures or 
esophageal rings often complicate longstanding reflux and could present 
in a similar fashion. 
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Pathology 
Squamous cell carcinoma is the most common histology seen in the 
esophagus (Figure 4). 
 
Figure 4. Invasive SCC of the esophagus showing normal squamous mucosa in 
the left upper corner of the picture (arrows). Nests of malignant cells with 
hyperchromatic and enlarged nuclei and forming keratin pearls are seen infiltrating 
into the lamina propria and muscularis in the middle and right side of the picture 
(arrowheads). Image courtesy of the University of Massachusetts Medical School, 
Department of Pathology. 
Adenocarcinoma (Figure 5a and 5b) is next most common, but incidence 
is rising rapidly in the developed world. 
 
Figure 5a. Invasive adenocarcinoma of the esophagus showing intestinal 
metaplasia (stars) in the left side of the picture, normal esophagus mucosa in the 
upper side of the picture (arrows). There are infiltrating malignant cells forming 
glands or ducts below normal squamous epithelium in the lamina propria 
(arrowheads). Image courtesy of the University of Massachusetts Medical School, 
Department of Pathology. 
 
Figure 5b. On high magnification, normal esophagus mucosa in the left upper side 
of the picture (arrows) and infiltrating malignant cells with hyperchromatic and 
enlarged nuclei and forming glands or ducts below normal squamous epithelium 
in the lamina propria (arrowheads) Image courtesy of the University of 
Massachusetts Medical School, Department of Pathology. 
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Much less common are gastrointestinal stromal tumor (GIST), 
leiomyosarcoma, lymphoma, carcinoid and melanoma of the esophagus 
are rare; melanomas may be metastatic from other sites. 
Diagnostic Workup 
When esophageal pathology is suspected on history and physical exam, 
searching for the cause usually involves upper endoscopy or barium 
swallow GI series, or both. While endoscopy is often recommended as a 
first test, a barium swallow can suggest a motility disorder, exclude 
esophageal diverticula as responsible for the symptoms, and reveal 
tumors, strictures, and other problems. When a probable cancer is seen 
on barium swallow (Figure 6), upper endoscopy is essential to confirm 
radiologic findings, obtain anatomic information such as tumor location, 
relationship to the gastroesophageal junction (GEJ), ulceration and 
luminal obstruction, and for possible stent placement. Biopsy is often 
performed at the time of endoscopy (Figure 7). 
 
Figure 6. 60-year-old male presented with progressive dysphasia. Spot 
radiograph from upper GI series demonstrates a circumferential narrowing (apple 
core lesion) in the distal esophagus, just proximal to the gastroesophageal (GE) 
junction. Note the irregular contour at the level of the esophageal narrowing 
secondary to mucosal ulceration and nodularity. Endoscopic biopsy revealed a 
poorly differentiated esophageal adenocarcinoma. Image courtesy of the 
University of Massachusetts Medical School, Department of Radiology. 
 
Figure 7. Circumferential large esophageal mass (arrow heads) obliterating the 
lumen of the esophagus. An ulcer (arrows) is noted on the mass. Image courtesy 
of the University of Massachusetts Medical School, Department of Medicine, 
Division of Gastroenterology. 
Once the diagnosis has been made, additional diagnostic studies are 
important for staging. Endoscopic ultrasound (EUS) has the capability to 
accurately evaluate the depth of esophageal lesions and whether there is 
invasion of surrounding structures (Figures 8, 9 and 10). 
 
Figure 8. Endoscopic Ultrasound image showing circumferential hypoechoic mass 
with loss of normal wall architecture (arrow heads) invading the adventitia (arrow). 
Image courtesy of the University of Massachusetts Medical School, Department of 
Medicine, Division of Gastroenterology. 
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Figure 9. Endoscopic Ultrasound image showing a well-defined hypoechoic 8.7 
mm X 8.3 mm round “plump” lymph node (arrowheads) next to the esophageal 
wall (red arrows) and adjacent to the aorta (yellow arrows). Image courtesy of the 
University of Massachusetts Medical School, Department of Medicine, Division of 
Gastroenterology. 
 
Figure 10. Endoscopic Ultrasound image showing non circumferential hypoechoic 
esophageal mass (yellow arrowheads) confined to the mucosa with a well 
preserved esophageal wall architecture (in between the red arrows). Image 
courtesy of the University of Massachusetts Medical School, Department of 
Medicine, Division of Gastroenterology. 
Additionally, the size, shape, and borders of involved lymph nodes can be 
assessed with sensitivity and specificity of 92% and 93% respectively. 
Coupled with fine needle aspiration (FNA) (Figures 11 and 12) EUS-FNA 
is highly sensitive in staging nodal disease. 
 
Figure 11. Endoscopic Ultrasound image showing FNA (Fine Needle Aspiration) 
(red arrow) of a para esophageal lymph node (yellow arrow heads). Image 
courtesy of the University of Massachusetts Medical School, Department of 
Medicine, Division of Gastroenterology. 
 
Figure 12. Cytology of the lymph node showing normal lymphocytes (red arrow) 
and malignant cells characterized by enlarged and variably shaped nuclei. Image 
courtesy of the University of Massachusetts Medical School, Department of 
Medicine, Division of Gastroenterology and Department of Pathology. 
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Computed tomography (CT) is often performed at diagnosis for local 
staging and to detect other sites of metastatic disease. It is also helpful for 
superior anatomic detail in surgical planning. Additionally, PET/CT is 
frequently performed as it provides superior sensitivity of nodal 
involvement and detects sites of disease that are otherwise not identified 
on conventional imaging techniques. PET/CT has been shown to upstage 
or downstage disease in approximately 24% of patients (Figure 13). 
 
Figure 13. PET/CT scan demonstrates a distal esophageal 18-FDG avid 
thickening that corresponds to the patients esophageal cancer (a,b). An 18-FDG 
avid metastatic gastrohepatic lymph node was also noted (c,d). CT scan (a,c); 
PET scan (b,d). Image courtesy of the UMass Memorial Hospital, Department of 
Diagnostic Radiology. 
Staging 
Staging of esophageal carcinoma is performed via the tumor (T), node (N) 
and distant metastasis (M) system, revised by the American Joint 
Committee on Cancer (AJCC) in 2016, effective January 2018, and 
available here. For esophageal cancer, T stage refers to the depth of 
tumor invasion as portrayed in Figure 14. Clinical staging uses all 
information available before surgery, including particularly endoscopic 
ultrasound, which can define depth of tumor penetration and local lymph 
node involvement, as well as PET/CT for regional and distant disease 
assessment. 
 
Figure 14. Cross section of esophageal wall depicting T stage according to depth 
of invasion through the various layers. Drawing by Rebecca M. Kwait, MD. 
Principles of Treatment 
Management of esophageal cancer requires a multidisciplinary approach, 
and all patients should be presented at a Tumor Board, with surgical, 
medical, radiation oncologists, diagnostic radiologist, pathologist and 
patient navigator present. Patients also benefit from early referral to a 
nutritionist and a palliative care team. 
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Surgery 
Surgical treatment of esophageal cancer may involve endoscopic mucosal 
resection, radical resection (esophagectomy), palliative resection (also 
esophagectomy) or placement of a stent. Esophagectomy is a complex 
operation. Historically high morbidity and mortality rates have improved 
with improvements in pre-operative staging modalities, surgical 
techniques and appropriate patient selection. 
For lesions 2 cm or smaller in size, endoscopic mucosal resection (EMR) 
may provide both diagnosis and cure. 
Although esophageal cancer typically presents at relatively advanced 
stages, surgical resection continues to be the mainstay of treatment for 
patients with more invasive disease (Stage Ib, II, IIIa). There are multiple 
surgical approaches to the resection of invasive (non-superficial) but 
potentially “curable” esophageal cancers. Discussion of surgical details is 
beyond the scope of this book, but removal of the esophagus requires re-
anastomosis of the gastrointestinal tract, with pull up of a more distal 
portion of the tract, often the stomach, into the chest. Figure 15 is the 
preoperative situation and Figure 16 is a postoperative gastric pull-up for 
reconstruction. 
 
Figure 15. Preoperative images of esophageal cancer in distal esophagus 1a. 
Tumor has extended to edge of esophagus, and not touched aorta. R0 resection 
is likely. Drawn by Sarah Alyssa Uy. 
 
Figure 16. Reconstruction of the gastrointestinal tract. Stomach has been 
mobilized and pulled up into the chest, then anastomosed to the proximal stump 
of the esophagus. Drawn by Sarah Alyssa Uy. 
To achieve an R0 resection, margins of normal esophagus must be 
obtained both proximally and distally; current recommendations are for 5 
cm margins. 
Patients with stage I tumors have high cure rates with surgery alone and 
do not generally require chemotherapy or radiation. If regional lymph node 
metastasis has occurred (stage IIb and III), the rate of cure with surgery 
alone is reduced to less than 20%. A meta-analysis of trials comparing 
neoadjuvant therapy followed by surgery with surgery alone suggests a 
13% absolute improvement in 2-year survival with combined therapy.17 
Chemotherapy and Radiation Therapy 
Preoperative chemoradiation is therefore recommended for Stages IIa, IIb 
and III in patients who are able to tolerate it. The preferred regimen is 
weekly carboplatin plus paclitaxel, based on the 2012 randomized phase 
III CROSS trial that demonstrated improvement in median survival from 
24 months with surgery alone to 49.4 months with neoadjuvant 
chemoradiation (p=0.003).13 As an alternative, a combination of cisplatin 
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plus 5-fluorouracil may be used along with radiation. Perioperative 
chemotherapy without radiation is also appropriate for tumors of the 
gastroesophageal junction based on the randomized, multicenter, phase 
III MAGIC trial.19 
Combined treatment with chemotherapy and radiation is superior to either 
chemotherapy or radiation alone and has achieved long term survival rates 
in up to 25% of patients. In patients who are poor surgical candidates due 
to serious medical comorbidities or poor functional status (Eastern 
Cooperative Oncology Group score>2), chemoradiation alone should be 
considered for localized disease (stage II or IIIa). Chemoradiation as 
definitive, nonsurgical therapy is more likely to achieve long term disease 
survival in patients with squamous cell carcinoma than in patients with 
adenocarcinoma. 
Radiation Therapy (RT) 
Radiation therapy for esophageal cancer is most effective when 
administered with radio-sensitizing chemotherapy. Because of the 
lymphatic tracts of the esophagus, which run predominantly longitudinally, 
skip metastases in the esophagus are common, and therefore, a long 
margin of apparently uninvolved esophagus must be treated to ensure 
adequate coverage of disease. In addition nodal metastases are common, 
so it is important to treat the lymph nodes at greatest risk of spread. These 
are referred to as first echelon nodes. For the lower third and the GEJ, the 
first echelon nodes include the celiac and gastrohepatic ligament nodes. 
To treat these nodal groups, much of the stomach must be treated. 
Because of the risk of tumor growing from the esophagus through the 
membranous posterior wall of the trachea, radiation oncologists usually 
require bronchoscopy prior to treatment, to know whether the tumor has 
grown through into the bronchial lumen. 
Radiation of the stomach is highly emetogenic. Inclusion of the stomach 
in the target volume can lead to significant mucosal irritation with profound 
nausea as an acute side effect. Modern anti-emetic medications have 
greatly decreased this problem. 
However because long sections of the esophagus must be treated, 
radiation esophagitis remains an issue, sometimes associated with 
candidiasis. Combination medications including antifungals, coating 
agents and local anesthetic agents have proven beneficial. Sometimes 
coating agents alone are sufficient, with the use of a bland, low acid, 
lukewarm, smooth diet or liquid supplements to permit adequate nutrition. 
Often despite treatments, nutritional intake is poor and insertion of a 
feeding tube is necessary so this is often done before treatment starts. 
However, patients who completely stop swallowing may be unable to 
resume eating normally after treatment, so it is important to encourage 
some daily oral intake. 
Patients who have had difficulty swallowing solids often experience 
improvement in swallowing ability after two to three weeks of radiation 
treatment, only to have the symptoms return as esophagitis develops. 
Medications can help in this situation to permit continued oral intake and 
avoidance of a feeding tube. 
Cancer of the Cervical Esophagus 
Cancer in the cervical esophagus is rare and is almost always of the 
squamous cell carcinoma type. Management has been controversial. In 
the pre-chemotherapy era, the results for surgery and radiation therapy 
were very similar, but given the rarity of this disease patient numbers are 
always very limited and most studies are retrospective case series. A 
randomized trial will probably never be feasible, as the annual number of 
cases is too small to conduct a study of this type in a reasonable time 
period. 
The anatomy of the esophagus in the neck previously mandated 
pharyngo-laryngo-esophagectomy for resection. However more recently 
larynx preserving resection has been described as a treatment option. 
Currently this disease is managed in the same fashion as other head and 
neck cancers, with resection or definitive concomitant chemoradiotherapy 
in an attempt to preserve the organs and cure the patient. Local failure 
after surgery is usually treated with radiotherapy with or without 
chemotherapy. Alternatively for more advanced tumors, local failure after 
radiotherapy alone may become amenable to surgical resection but 
operating on radiated tissue in the neck is fraught with high rates of 
anastomotic failure.20 
Supportive Care during Definitive Therapy 
Patients with significant tumor obstruction may require local measures 
such as esophageal stent placement or percutaneous feeding tube 
insertion to maintain adequate hydration and nutrition during 
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chemoradiation or chemotherapy. Multidisciplinary consultation is required 
to determine the optimal procedure with consideration of risks including 
stent complications, and peritoneal seeding from endoscopic feeding tube 
placement. The need to preserve the distal stomach for future 
anastomosis and the possibility of performing diagnostic laparoscopy to 
evaluate for peritoneal disease must also be considered,so the standard 
of care is placementof a tube in the jejunum (J-tube), rather than the 
stomach (gastrostomy tube (G-tube) or percutaneous endoscopic 
gastrostomy tube (PEG)). Consultation with a nutritionist is also 
appropriate to optimize nutrition perioperatively. 
Physical activity also enhances tolerance of treatment. A small 
randomized trial of weekly nutritional counselling plus supervised walking 
for 20 minutes three times a week found improved nutritional status, 
functional walking capacity, grip strength and implied quality of life 
compared to a usual care group.21 
Therapy for Incurable Disease  
More than half of patients present with either locally extensive tumor 
spread (T4) that is unresectable or distant metastases (M1) (stage IIIB or 
IV). Surgery is usually not warranted in these patients. Similarly, the 
majority of patients with Stages II and III esophageal cancer who are 
treated with chemoradiation and/or surgery will relapse with metastatic 
disease, most within three years of initial diagnosis. Since prolonged 
survival can be achieved in only a few patients, the primary goal of 
treatment of metastatic disease is to provide relief from dysphagia and 
pain, optimize quality of life and minimize treatment side effects. The 
optimal palliative approach depends on the presence or absence of 
metastatic disease, expected survival, patient preference and institutional 
experience. Many patients with advanced disease may prefer concerted 
efforts at pain relief and care directed at symptom management. 
Chemotherapy and Chemoradiation 
Combined radiation and chemotherapy may achieve palliation in two-
thirds of patients with unresectable tumor, but is associated with significant 
side effects. It should be considered for all patients with locally advanced 
tumors without distant metastases (stage IIIb) who have good functional 
status with no significant medical problems. Improvement in dysphagia 
occurs within 2-4 weeks in almost 90% of patients, and is sometimes 
associated with long term survival. 
Combination chemotherapy may also be considered in those patients with 
metastatic disease who still have good functional status and expected 
survival of at least several months. Three drug combinations commonly 
include a fluoropyridimine (5-fluorouracil or capecitabine), a platinum drug 
(cisplatin or oxaliplatin), and either epirubicin or a taxane (docetaxel or 
paclitaxel). However, three drug regimens are also quite toxic. Only 
patients with a very good performance status should be offered a three-
drug combination. Most patients with metastatic esophageal cancer will be 
best served with a two drug regimen. 
Roughly 15%-20% of adenocarcinomas of the G-E junction overexpress 
HER-2 (human epidermal growth factor receptor 2). Patients with these 
cancers who have metastatic disease should be treated with the anti-
HER2 monoclonal antibody trastuzumab in addition to a fluoropyrimidine 
and platinum agent.22 
Current initial chemotherapy will produce a meaningful response in only 
about 20%-30% of patients. The duration of tumor responses is usually 
around four to six months. Hence, almost all patients with metastatic 
esophageal cancer will either not respond to initial treatment, or develop 
progressive disease within the first year after starting treatment. At the 
time of progression, many patients will be best served with palliative 
treatments, including hospice care. A few patients may have a good 
enough functional status to warrant additional treatment. These patients 
will typically be treated with a single chemotherapy drug, rather than 
combination chemotherapy. 
Recently, the monoclonal antibody ramucirumab was approved either 
alone, or in combination with paclitaxel, as treatment for adenocarcinoma 
of the GE (gastroesophageal) junction in patients who relapsed after initial 
treatment with a platinum-based regimen. Ramucirumab targets the 
vascular endothelial growth factor receptor.23 
In light of the poor outcomes of patients with metastatic esophageal cancer 
after treatment with currently available therapies, referral of patients to an 
appropriate clinical trial is also a very reasonable option. Regardless of 
whether a patient enters an investigational study, is treated with standard 
therapy, or foregoes anti-cancer treatment, all patients with metastatic 
esophageal cancer should be referred for a palliative care consultation. 
Goals of care should be discussed frequently throughout the course of a 
patient’s illness and hospice referral should be considered when 
appropriate. 
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Immunotherapy 
Immunotherapy has, as yet, no clinical role in either esophageal cancer. It 
does remain under preclinical investigation, particular for AC.24 
Local Therapy for Esophageal Obstruction 
Patients with advanced esophageal cancer often have poor functional and 
nutritional status. Radiation therapy alone to the area of esophageal 
obstruction may afford short term relief of pain and dysphagia. This can 
generally be performed in a short course over a few weeks but may be 
complicated by temporary worsening of dysphagia and odynophagia. 
Rapid palliation of dysphagia may be achieved by peroral placement of 
permanent expandable wire stents (alone or followed by radiation to 
minimize tumor progression back into the stented lumen). Stents are most 
commonly used because of their relative ease of placement. Although 
dysphagia and quality of life are improved, patients seldom can eat 
normally after stent placement. Complications occur in 20-40% and 
include perforation, migration, and tumor ingrowth. 
For a few medically appropriate patients, palliative resection may be 
considered because it may provide the most rapid palliation of obstruction. 
Finally, after careful discussion with patient and family, Palliative feeding 
tube placement may be considered for hydration and nutrition in selected 
cases if the obstruction is not amenable or is refractory to stenting, 
radiation or other local therapies. However, patients must be aware that 
such feeding is unlikely to significantly prolong life.  
Outcome 
Depending on stage, neoadjuvant chemoradiation can be incorporated to 
reduce the bulk of disease and decrease surgical complications. While the 
evaluation of chemotherapeutic agents has been hampered by ambiguity 
in the definition of “response” and the debilitated physical condition of 
many treated patients, significant reductions in the size of tumor masses 
have been reported. In 15-25% of patients given single-agent treatment 
and in 30-60% of patients treated with drug combinations including 
cisplatin, there is partial regression of the tumor. As a result the use of 
neoadjuvant chemoradiation followed by resection appears to prolong 
survival as compared with resected controls in many small randomized 
trials and has become standard for invasive cancers. 
Early diagnosis improves outcome.1 Very small lesions are amenable to 
local resection with EMR. Regardless of preoperative stage, total resection 
of all gross tumor is feasible in only 45% of cases, with residual tumor cells 
frequently present at resection margins leading to anastomotic 
recurrences. Additionally, surgical complications such as anastomotic 
leaks, fistulas, subphrenic abscesses, mediastinitis and respiratory or 
cardiac complications also contribute to poor outcomes with a 5-year 
survival rate of 20% after a total resection. 
Definitive concomitant chemoradiotherapy may provide comparable 5-
year survival and is a reasonable option, especially for patients with 
squamous cell carcinoma or medical comorbidities. 
Regardless of the histology, and despite treatment advances, even for 
patients with localized disease, the chance of long term survival is limited. 
Because of the rich lymphatic network of the esophagus, cancers in this 
structure tend to metastasize early. Therefore the prognosis of patients, 
despite treatment advances, for patients with esophageal carcinoma is 
poor even for patients with localized disease of either histology. Fewer 
than 15% of patients survive five years after the diagnosis, so 
management often aims for symptom control rather than cure. 
However, even for patients with metastatic disease there is now some 
hope of progress. Trials of checkpoint inhibitors with or without radiation 
therapy, vaccines and other modalities show promise andare ongoing.25  
Conclusion 
Cancer of the esophagus should be thought of as two different diseases, 
with similar treatment at this time. As it tends to spread early and present 
with locally advanced disease, prognosis is poor, although a few patients 
are cured. Treatment requires a multidisciplinary team, and should include 
nutritional support and early palliative care referral.  
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Thought Questions 
1. What is the relationship between obesity and incidence of 
esophageal cancer? 
Your answer: 
 
 
 
 
 
 
 
 
 
 
 
Expert Answer 
 
 
 
 
 
2. What makes the management of esophageal carcinoma so morbid? 
 
Your answer: 
 
 
 
 
 
 
 
 
 
 
 
 
Expert Answer 
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3. Why is the prognosis of esophageal cancer, no matter the histology, 
so poor? 
Your answer: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Expert Answer 
 
4. What factors have influenced the changing prevalence of esophageal 
adenocarcinoma in the United States? 
Your answer: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Expert Answer 
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5. Why is it important to document patient’s use of histamine receptor 
antagonists or proton pump inhibitors? 
Your answer: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Expert Answer 
 
Glossary 
18-FDG - 18-Fludeoxyglucose 
Boilermaker – A drink combining a shot of whiskey and a glass of beer, 
consumed either as a mixture or sequentially. 
Gastrointestinal stromal tumor (GIST) – Mesenchymal tumor of the GI tract 
Leiomyosarcoma – Smooth muscle connective tissue tumor 
Eastern Cooperative Oncology Group (ECOG) score – Performance 
status scale used to assess how a patient’s disease is progressing. Scale 
0-5, 0 being fully active and 5 being dead. 
Emetogenic – Causing nausea and perhaps vomiting 
Hematemesis - Vomiting blood 
Mate – A tea from South America made from yerba mate leaves, often 
served very hot. 
Melena – Black stool, due to iron in the stool, usually from digested blood 
Pharyngo-laryngo-esophagectomy – Removal of the hypopharynx, larynx 
and esophagus with permanent tracheostomy 
R0 resection – Complete removal of all gross disease 
Skip metastases – Deposits of cancer cells (tumors) in the esophagus at 
a distance from the primary tumor. These are thought to arise from cells 
travelling in the longitudinal lymphatic channels in the esophageal wall. 
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